The Drug Discovery World Podcast Drug Discovery World (DDW)

This is the latest episode of the free DDW narrated podcast, titled “The future climate and landscape for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW.
They are called: Pharma’s important climate and What will the 2023 drug discovery landscape look like?
In the first article, DDW Editor Reece Armstrong comments of the impact of climate change in the drug discovery sector.
In the second article, DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which 2023 will lean.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   
In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic.
The drug targets receptors in the gut where it triggers cholecystokinin (CCK), a GI system peptide hormone responsible for stimulating the digestion of fat and protein. CCK stimulates pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and sends a signal to the brain that one has had enough to eat.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the discovery of molecular doorways that could be used to help deliver drugs into the brain to treat neurological disorders, a plant-based medication which may be an effective therapy to help patients stop vaping, immune B cells which could be used to develop cancer targeting immunotherapies, and positive top-line results in Phase II/III study in schizophrenia patients.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. 
The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment, this money enables scientists to produce top-quality research which will in turn result in discoveries and drugs that help tackle disease and areas of unmet need. Here are five financial success stories that made headlines this week.
You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   
In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.
Dr Worland has significant experience as a scientist and C-suite level executive/entrepreneur, and today speaks about how Selective Translation Regulator Inhibitors (STRIs) are unique to other cancer treatments, the future of the industry as well as the significance of pharma collaboration in the development process.
You can find the Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.